Back
 

View:
Mini 
BasicThis view is available after user registration.
 
ShortThis view is available when you buy a license.
 
StandardThis view is available when you buy a license.
 
CompleteThis view is available when you buy a license.
 

Crizotinib 250, Non-Small Cell Lung Cancer (ALK+), Second Line

Protocol-ID: 198 V1.1 (Mini), CRIZ250, NSCLC (ALK+), second line

Indication(s)

  • Lung Carcinoma, Non-Small Cell (ALK+); ICD-10 C34.-

Links

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. [PMID]
The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 07.11.2021